ASCO GI: Mixed Results for Liposomal Irinotecan

SAN FRANCISCO (MedPage Today) — A randomized trial of liposomal irinotecan (PEP02) in gastric cancer yielded mixed results, achieving the primary objective of tumor shrinkage but without improving disease control rates or survival.

Post a Comment

Comments are closed.